Navigation Links
Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
Date:4/20/2012

CHAPEL HILL, N.C., April 20, 2012 /PRNewswire/ -- There are some two dozen oncology therapies in Phase III testing and many more are in earlier stages of development. While only some of these therapies will make it to launch, those that do will face yet another hurdle: a competitive marketplace where success revolves around planning as much as science.

In this environment, pharmaceutical organizations in the oncology therapeutic area must constantly evaluate which factors play the biggest role in the current launch landscape. One pharma company with promising products in its development pipeline wanted to know what launch success and failure factors play the biggest role in the current launch environment.

To answer this question, Best Practices, LLC conducted a wide-ranging field research project that explores the pivotal success factors and failure points facing new oncology product launches. The research established a critical core set of factors that can make or break a market entry for cancer products as well as other types of therapies.

The study, Success Factors and Failure Points in Oncology Product Launches, presents a framework for launch success:

  • The ability to differentiate
  • A defined target patient population
  • Investment in launch activities
  • Engagement of thought leaders
  • Education of key stakeholders
  • Demonstration of value
  • Utilization of new technologies
  • Avoidance of launch pitfalls

In terms of educating and winning support from key stakeholders, the study found that companies need to focus on different constituents during three critical early periods in a product's lifecycle (Market Entry, Win Share and Grow Share).

When entering the market, oncology launch leaders said companies need to focus on educating KOLs and payers; when trying to win share, the focus shifts to KOLs and specialists; and when trying to grow market share, it's important to focus on specialists and policymakers/government.

The 173-page report examines each of the key issues that are part of the framework for launch success and offers launch leaders two perspectives: an oncology segment and a total benchmark class segment that includes other therapeutic areas. In addition to delivering qualitative and quantitative insights on each aspect of this launch framework, the report presents launch leaders' perspectives on the current and future risk levels for an array of pitfall factors that can affect a launch.

To download a complimentary study excerpt, go to: http://www3.best-in-class.com/re1905.htm.

Best Practices, LLC used both field surveys and interviews to complete this study. In all, 44 managers and executives at 38 leading bio-pharma companies participated in the survey.  In-depth interviews were conducted with leaders from six organizations.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Cepheid Reports 2012 First Quarter Results
3. New Report - Computed Tomography (CT) Market is Expected to Reach USD 5.6 Billion Globally in 2017: Transparency Market Research
4. Sotera Wireless Reports FDA Clearance of ViSi Mobile™ System
5. Masimo to Report First Quarter 2012 Financial Results after Market Close on May 2
6. Solta Medical to Report First Quarter 2012 Results Release and Host Conference Call on May 1
7. Pharmos Corporation Reports First Quarter 2012 Results
8. Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations
9. NxStage® to Report First Quarter Fiscal 2012 Financial Results
10. Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012
11. Assured Pharmacy Reports Results for the Fiscal Year 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 27, 2016 According to the ... is driving ambulatory blood pressure monitoring system market growth. ... their ability to respond to different pressure rates, leading ... lead to various cardiovascular disorders such as heart failure, ... diseases are growing in prevalence each year. WHO estimates ...
(Date:5/27/2016)... -- Amarantus BioScience Holdings, Inc. (OTCQX: ... Medicine, Neurology and Orphan Diseases, today announced that President & CEO ... investor conferences: SeeThru Equity MicroCap Conference   ... York City , NY When: Tuesday, May 31 ...   Where: Grand Hyatt Hotel, 109 East 42 nd ...
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... 2016 , ... Spartan Bioscience today introduced the Spartan Cube, ... , The Cube is exceptionally small—it takes up the space of a coffee ... any space, whether in a hospital, doctor’s office, or pharmacy. , The device’s ...
(Date:5/31/2016)... ... May 31, 2016 , ... The successful implementation of ... their laboratories as well. However, laboratories have different challenges compared to manufacturing environments. ... operations in the lab, METTLER TOLEDO has developed the Lean Lab Checklist . ...
(Date:5/31/2016)... , ... May 31, 2016 , ... The Global ... today released ten predictions on the future of wellness, travel, spa and beauty in ... travel, spa and beauty companies to leading economists and researchers - to forecast where ...
(Date:5/31/2016)... ... ... In his latest video, renowned AstroNumerologist Jesse Kalsi reveals ... candidate Donald Trump as an example, Kalsi describes the way AstroNumerology conveys the ... numbers up,” says Kalsi. “It is about looking at each individual number, since ...
(Date:5/31/2016)... ... ... The Orthopaedic Research and Education Foundation (OREF) is pleased to announce the ... his term as president in March, succeeding John J. Callaghan, MD, who remains on ... F. Kyle, MD, will serve as chair, corporate development, succeeding Thomas P. Schmalzried, MD, ...
Breaking Medicine News(10 mins):